MedPath

Cytarabine

Generic Name
Cytarabine
Brand Names
Cytosar, Vyxeos
Drug Type
Small Molecule
Chemical Formula
C9H13N3O5
CAS Number
147-94-4
Unique Ingredient Identifier
04079A1RDZ
Background

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication

For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-
Clinical Trials
Related News

CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma

Phase 1
Withdrawn
Conditions
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Follicular Lymphoma
CD19 Positive
Refractory Diffuse Large B-Cell Lymphoma
Mantle Cell Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Recurrent Follicular Lymphoma
Interventions
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Biological: Filgrastim
Drug: Melphalan
Biological: Rituximab
Biological: Umbilical Cord Blood-derived Natural Killer Cells
First Posted Date
2018-07-09
Last Posted Date
2020-01-29
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT03579927
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

Phase 2
Recruiting
Conditions
Multiple Myeloma
Interventions
Drug: Allopurinol
Drug: Carmustine
Drug: Melphalan
Drug: Etoposide
Drug: Cytarabine
First Posted Date
2018-06-27
Last Posted Date
2022-06-22
Lead Sponsor
Swedish Medical Center
Target Recruit Count
100
Registration Number
NCT03570983
Locations
🇺🇸

Swedish Cancer Institute, Seattle, Washington, United States

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

First Posted Date
2018-06-27
Last Posted Date
2024-12-20
Lead Sponsor
University of Chicago
Target Recruit Count
15
Registration Number
NCT03571321
Locations
🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

Atovaquone (Mepron®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML)

Early Phase 1
Active, not recruiting
Conditions
Acute Myeloid Leukemia
Interventions
Drug: Atovaquone
Drug: Cytarabine
Drug: Daunorubicin
Drug: Etoposide
Drug: Gemtuzumab Ozogamicin
First Posted Date
2018-06-26
Last Posted Date
2024-11-21
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
26
Registration Number
NCT03568994
Locations
🇺🇸

Baylor College of Medicine - Texas Childrens Hospital, Houston, Texas, United States

🇺🇸

Johns Hopkins Medicine, Baltimore, Maryland, United States

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL

Phase 2
Conditions
Leukemia
Adult Lymphoblastic Lymphoma
Adult Acute Lymphoblastic Leukemia
Leukemia, Lymphoblastic
Leukemia, T Cell
Lymphoblastic Lymphoma
Leukemia, Acute
Lymphoblastic Leukemia
Interventions
Drug: Dexamethasone
Drug: vincristine
Drug: Cyclophosphamide
Drug: Idarubicin
Drug: Pegaspargase
Drug: Adriamycin
Drug: Methotrexate
Drug: 6-mercaptopurine.
Drug: Etoposide
Drug: Cytarabine
Procedure: Bone marrow aspiration
Procedure: Intrathecal injection
Radiation: Radiation therapy
Genetic: NGS
Procedure: allogeneic hematopoietic stem cell transplantation
Diagnostic Test: Flow-MRD
Diagnostic Test: FISH
Diagnostic Test: Flow immunophenotyping
Diagnostic Test: Karyotyping
Drug: Chidamide
Diagnostic Test: PET-CT scan
First Posted Date
2018-06-21
Last Posted Date
2018-06-21
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
80
Registration Number
NCT03564704
Locations
🇨🇳

Department of Hematology, Nanfang Hospital, Guangzhou, Guangdong, China

A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia

Phase 1
Completed
Conditions
Acute Myeloid Leukemia
Interventions
Drug: Alvocidib
Drug: Cytarabine
Drug: Mitoxantrone
Drug: Daunorubicine
First Posted Date
2018-06-20
Last Posted Date
2022-04-12
Lead Sponsor
Sumitomo Pharma Co., Ltd.
Target Recruit Count
10
Registration Number
NCT03563560
Locations
🇯🇵

Fukui University Hospital, Yoshida-gun, Fukui, Japan

🇯🇵

Chugoku Central Hospital, Fukuyama, Hiroshima, Japan

🇯🇵

Hokkaido University Hospital, Sapporo, Hokkaido, Japan

and more 8 locations

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL

Phase 2
Conditions
Leukemia, Acute
Leukemia, T Cell
Leukemia, Lymphoblastic
Interventions
Drug: Chidamide
Drug: Dexamethasone
Drug: vincristine
Drug: Cyclophosphamide
Drug: Idarubicin
Drug: Pegaspargase
Drug: Adriamycin
Drug: Methotrexate
Drug: 6-Mercaptopurine
Drug: Etoposide
Drug: Cytarabine
Procedure: Bone marrow aspiration
Procedure: Intrathecal injection
Radiation: Radiation therapy
Genetic: NGS
Procedure: allogeneic hematopoietic stem cell transplantation
Diagnostic Test: Flow-MRD
Diagnostic Test: FISH
Diagnostic Test: Flow immunophenotyping
Diagnostic Test: Karyotyping
First Posted Date
2018-06-12
Last Posted Date
2018-06-12
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
70
Registration Number
NCT03553238
Locations
🇨🇳

Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

Phase 1
Completed
Conditions
Acute Myeloid Leukemia
Interventions
Drug: Cladribine
Drug: Cytarabine
Drug: Gemtuzumab Ozogamicin
Biological: Recombinant Granulocyte Colony-Stimulating Factor
Other: Laboratory Biomarker Analysis
Drug: Mitoxantrone Hydrochloride
First Posted Date
2018-05-22
Last Posted Date
2023-08-30
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
66
Registration Number
NCT03531918
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia

Phase 1
Terminated
Conditions
Blasts 5 Percent or More of Bone Marrow Nucleated Cells
Secondary Acute Myeloid Leukemia
T Acute Lymphoblastic Leukemia
Myelodysplastic/Myeloproliferative Neoplasm
Philadelphia Chromosome Positive
Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Recurrent Acute Lymphoblastic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Refractory Acute Lymphoblastic Leukemia
Interventions
Drug: Cytarabine
Other: Laboratory Biomarker Analysis
Biological: Recombinant EphB4-HSA Fusion Protein
Drug: Vincristine Liposomal
First Posted Date
2018-05-09
Last Posted Date
2021-11-30
Lead Sponsor
University of Southern California
Target Recruit Count
3
Registration Number
NCT03519984
Locations
🇺🇸

USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 2
Terminated
Conditions
Recurrent B Acute Lymphoblastic Leukemia
Philadelphia Chromosome Negative
Refractory B Acute Lymphoblastic Leukemia
Interventions
Biological: Blinatumomab
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Mercaptopurine
Drug: Methotrexate
Biological: Pegfilgrastim
Biological: Rituximab
Drug: Vincristine Sulfate
First Posted Date
2018-05-08
Last Posted Date
2022-11-04
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
6
Registration Number
NCT03518112
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy